A 3-step acne system containing solubilized benzoyl peroxide versus clindamycin-benzoyl peroxide

Cutis

Volumn 84, Issue 1, 2009, Pages 48-55

  Thiboutot, Diane ^a   Eichenfield, Lawrence ^b   Shalita, Alan ^c   Del Rosso, James Q ^d   Swinyer, Leonard ^e   Tanghetti, Emil ^f   Tschen, Eduardo ^g   Parr, Lisa ^h  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b Children's Specialists of San Diego   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

^d Las Vegas Skin & Cancer Clinics Ltd   (United States)

^e Dermatology Research Center   (United States)

^f Center for Dermatology and Laser Surgery   (United States)

^g Academic Dermatology Associates   (United States)

^h Obagi Medical Products Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BENZOYL PEROXIDE; CLINDAMYCIN; DERMATOLOGICAL AGENT; KERATOLYTIC AGENT; SALICYLIC ACID;

ACNE VULGARIS; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; GEL; HUMAN; INTRADERMAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SOLUBILITY; TIME; TREATMENT OUTCOME;

ACNE VULGARIS; ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BENZOYL PEROXIDE; CHILD; CLINDAMYCIN; DERMATOLOGIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; GELS; HUMANS; KERATOLYTIC AGENTS; MALE; MIDDLE AGED; SALICYLIC ACID; SOLUBILITY; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70349312543     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Belknap BS. Treatment of acne with 5% benzoyl peroxide gel or 0.05% retinoic acid cream. Cutis. 1979;23:856-859.
2. Parry EJ, Griffiths CE. Bacteria and antimicrobial agents in the treatment of acne. Int J Dermatol. 1996;35: 249-251.
3. Gollnick H, Cunliffe W, Berson D, et al; Global Alliance to Improve Outcomes in Acne. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(suppl 1):S1-S37.
4. Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. Cutis. 2007;79(suppl 6):9-25.
5. Chellquist EM, Gorman WG. Benzoyl peroxide solubility and stability in hydric solvents. Pharm Res. 1992;9: 1341-1346.
6. Otberg N, Richter H, Schaefer H, et al. Variations of hair follicle size and distribution in different body sites. J Invest Dermatol. 2004;122:14-19.
7. Data on file. Long Beach, CA: Obagi Medical Products, Inc; 2006.
8. Erianne J, Prince DL, Ramirez J, et al. The pharmacologic science of a novel benzoyl peroxide formulation and the implications for clinical effects. Poster presented at: 25th Anniversary Fall Clinical Dermatology Conference; October 6-9, 2006; Las Vegas, NV.
9. Del Rosso JQ. Evaluation of a solubilized benzoyl peroxide gel: a pooled analysis from 3 randomized investigator-blinded trials. Cosmet Dermatol. 2008;21:201-206.
10. CLENZIderm M.D. product overview. Obagi Medical Products, Inc, Web site. http://www.obagi.com/article/forpatients/ourproducts/obagiclenzidermmd/products/products.html. Accessed June 4, 2009.
11. Green LJ. Efficacy and tolerability of a 3-step acne system containing a novel solubilized benzoyl peroxide lotion for normal to dry skin versus a benzoyl peroxide/clindamycin combination product: an investigator-blind, randomized, parallel-group study. Poster presented at: 66th Annual Meeting of the American Academy of Dermatology; February 1-5, 2008; San Antonio, TX. P110.
12. Tanghetti E, Kircik L, Wilson D, et al. Solubilized benzoyl peroxide versus benzoyl peroxide/clindamycin in the treatment of moderate acne. J Drugs Dermatol. 2008;7:534-538.
13. Eady EA, Bojar RA, Jones CE, et al. The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin-resistant propionibacteria. Br J Dermatol. 1996;134:107-113.
14. Mills O Jr, Thornsberry C, Cardin CW, et al. Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle. Acta Derm Venereol. 2002;82: 260-265.
15. Vowels BR, Feingold DS, Sloughfy C, et al. Effects of topical erythromycin on ecology of aerobic cutaneous bacterial flora. Antimicrob Agents Chemother. 1996;40:2598-2604.
16. Cunliffe WJ, Holland KT, Bojar R, et al. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther. 2002;24:1117-1133.
17. Harkaway KS, McGinley KJ, Foglia AN, et al. Antibiotic resistance patterns in coagulase-negative staphylococci after treatment with topical erythromycin, benzoyl peroxide, and combination therapy. Br J Dermatol. 1992;126: 586-590.
18. Levy RM, Huang EY, Roling D, et al. Effect of antibiotics on the oropharyngeal flora in patients with acne. Arch Dermatol. 2003;139:467-471.
19. Margolis DJ, Bowe WP, Hoffstad O, et al. Antibiotic treatment of acne may be associated with upper respiratory tract infections. Arch Dermatol. 2005;141:1132-1136.
20. Kligman AM. Acne vulgaris: tricks and treatments. part II: the benzoyl peroxide saga. Cutis. 1995;56: 260-261.